Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer

Table 3 Clinical characteristics of patients who received CIT for ≥ 3 courses or < 3 courses

Clinical features	CIT ≥ 3 courses	CIT < 3 courses	P-value
Sex
Male	11	11	0.187
Female	6	1	0.187
Age, years
Median (range)	61 (41–79)	64 (54–78)	0.107
Smoking index
Median (range)	400 (0–1000)	350 (0–2000)	0.751
ECOG
≤1	16	9	0.279
2	1	3	0.279
Chemotherapy courses
Median	6	6	0.713
Range	4–6	4–6	0.713
Radiotherapy
Yes	16	9	0.279
No	1	3
Surgery
Yes	3	1	0.622
No	14	11	0.622
Chemotherapy responses *
CR	5	2	0.707
PR	7	7
SD	5	3
Stage
Limited	10	7	1.000
Extensive	7	5	1.000

Abbreviations: CIT, cellular immunotherapy; ECOG, Eastern Cooperative Oncology Group; CR, complete remission; PR, partial remission; SD, stable disease
Note: *The responses for the first-line therapy

ISSN: 1479-5876